With the market underpricing its earnings stability and future catalysts, Pfizer presents a compelling defensive investment ...

Vepdegestrant (ARV-471) yielded a statistically significant and clinically meaningful improvement in progression-free ...

Pfizer and Arvinas' experimental breast cancer treatment failed to delay the progression of the disease in a broader group of patients in a late-stage trial, sending the Connecticut-based biotech's ...

Early toxicities associated with a 3-week hypofractionated radiotherapy regimen do not raise initial safety concerns in women ...

Phase III VERITAC-2 trial results show vepdegestrant significantly improved progression-free survivalcompared to fulvestrant ...

An experimental breast cancer treatment co-developed by Pfizer and Arvinas significantly improved the time some patients lived without the disease worsening, but failed to achieve statistically ...

The phase 3 VERITAC-2 trial has been evaluating the candidate against AstraZeneca’s endocrine therapy Faslodex (fulvestrant) ...

Topline results from the Phase III VERITAC-2 trial found that vepdegestrant provided a statistically significant and ...

Moffitt Cancer Center researchers have discovered a promising new vaccine strategy for treating a specific type of breast cancer. The innovative approach targets human epidermal growth factor receptor ...